Faeth was born from three leading research teams with three separate discoveries coming together around one big idea: We can use metabolism to beat cancer.
3 teams, 3 discoveries
one paradigm shift
The science of cancer meets the power of metabolism
Cancer therapies have remained largely unchanged for decades. At Faeth, we believe that the use of metabolism and precision nutrition will join surgery, radiotherapy, small molecules (e.g. chemotherapy, targeted therapies), and biologics (e.g. immunotherapy, antibodies) as a foundational treatment for cancer.
Faeth is a data-driven, evidence-based company with a deep mechanistic understanding of the way that dietary nutrients influence tumor growth and cancer treatment. We are fully focused on matching specific diets with tumor genotypes and treatment regimens to improve the outcomes of cancer therapy, and we’re in clinical trials now.
Using metabolism and precision nutrition to starve cancer of the nutrients it needs to grow and resist treatment has the potential to transform the efficacy of conventional cancer therapies.
Our mission is to help every cancer patient use the power inside them to beat their cancer with world-leading science and precision nutrition.
Our team of world-leading scientists and founders
Associate Director of Basic and Translational Research, UCLA Johnson Comprehensive Cancer Center; Professor of Biological Chemistry, David Geffen School of Medicine at UCLA; Co-Director, UCLA Metabolomics Center
Investigator, Howard Hughes Medical Institute; Chief of the Division of Genetics and Metabolism in the Department of Pediatrics, UT Southwestern Medical Center
Matthew Vander Heiden
Associate Professor of Biology, MIT; Associate Director, Koch Institute for Integrative Cancer Research